IL-6/STAT3 activity often correlates with tumorigenesis and poor prognosis in humans, processes which are linked to the gp130-signaling pathway.3 Moreover, somatic mutations coding for constitutively activated gp130 have been detected in hepatocellular adenoma.43 Indeed, clinical trials with IL-6 antibodies have shown good antitumor efficacy leading, yet, massive systemic elevations in IL-6. Here, STAT3 is linked to hepatocellular adenoma.